Physician profile
Ramon Lee
NPI 1194119339
$18,720.05
in general payments reported to CMS, 2019-2025
24 companies · $2,933 in 2025
The $2,933 reported for 2025 was more than what 85% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $468 · 2021: $61.68 · 2022: $280 · 2023: $2,213 · 2024: $11K · 2025: $2,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,020 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $2,683 · Honoraria: $1,200 · Travel and Lodging: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,020.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $2,683.42 |
| Honoraria | $1,200.00 |
| Travel and Lodging | $459.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $8,321.84 | 2024 | Eylea Hd |
| Bausch & Lomb Americas INC. | $4,000.00 | 2024-2025 | Xiidra, Lotemax, Xipere |
| Alimera Sciences, INC. | $2,041.95 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $521.58 | 2023-2024 | Izervay |
| Regeneron Healthcare Solutions, INC. | $423.55 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $383.24 | 2019-2020 | |
| Thea Pharma INC. | $350.00 | 2025 | |
| Abbott Laboratories | $338.55 | 2023-2025 | Perclose Prostyle, Dragonfly Opstar, Xience Skypoint |
| Genentech USA, INC. | $331.97 | 2019-2025 | Susvimo |
| Alcon Vision LLC | $295.94 | 2019 | |
| Apellis Pharmaceuticals, INC. | $289.70 | 2022-2025 | Syfovre |
| Abbvie INC. | $251.81 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.85 | 2019 | |
| Coherus Oncology, INC. | $162.44 | 2022-2024 | |
| Cardinal Health 110 LLC | $150.00 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $123.12 | 2023 | |
| Allergan, INC. | $105.13 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $97.80 | 2019 | |
| Eyepoint US, INC. | $72.29 | 2019-2021 | |
| Sandoz INC. | $55.59 | 2024 | Cimerli |
| Notal Vision, INC. | $46.47 | 2022 | |
| Amgen INC. | $44.39 | 2019-2025 | Pavblu |
| Shockwave Medical, INC | $31.82 | 2022 | |
| Heartflow, INC. | $31.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.